Insulet Launches New Educational iPad App: Toby’s T1D Tale

Omnipod® Mascot Provides Diabetes Education to
Children and Caregivers through Stories, Tips and Trivia

BILLERICA, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader
in tubeless insulin pump technology with its Omnipod® Insulin
Management System (Omnipod System), today announced the introduction of
a new educational app at the 17th annual Children with Diabetes “Friends
for Life®” conference in Orlando, Florida. The free app,
Toby’s T1D Tale, is designed to educate children and caregivers about

The app features the Omnipod System mascot Toby the Turtle,
who uses the Omnipod System to manage his Type 1 diabetes. The app
chronicles his journey from diagnosis to treatment as he, his family and
his friends learn how to manage diabetes. Each stage of Toby’s journey
is detailed in chapters that can be read or listened to and then
expanded upon with actionable tips and trivia questions. In addition to
children with diabetes and their immediate caregivers, the app also
serves as a helpful tool for teachers, coaches, and friends.

“As any parent of a child with diabetes knows, helping children
understand and cope with the disease can be challenging. This app will
play a key role in diabetes education and management because it offers
easy-to-understand information that those with and connected to diabetes
can use in a tangible way. It truly delivers engaging content that is
relevant to people of all ages,” said Cindy Wright, mom of Podder
Trent Wright, age 12.

“We’ve worked closely with several providers, including a pediatric
psychologist, caregivers and our clinical team to deliver a credible
resource that resonates with and provides our growing Podder community
with the most useful information to manage their diabetes,” said Shacey
Petrovic, President, Insulet Diabetes Products. “Together with our
recent debut of the new Omnipod mobile Patient App, as well as our new
branding and presence on social media, this introduction of Toby’s T1D
Tale is yet another step in our journey to engage, inform and empower
the diabetes community through innovative mobile connectivity.”

Insulet’s Omnipod System employs differentiated technology that
dramatically improves the lives of approximately 85,000 users worldwide
– known as members of the Podder community. The app is currently
available for iPad users in the United States and can be downloaded from
the Apple Store by searching for Toby’s T1D Tale or by clicking

About the Omnipod Insulin Management System:

The Omnipod Insulin Management System is an innovative continuous
insulin delivery system that provides all the proven benefits of
continuous subcutaneous insulin infusion (CSII) therapy in a way no
conventional insulin pump can. The Omnipod System’s innovative design
and features allows people living with diabetes to live their life—and
manage their diabetes—with unprecedented freedom, comfort, convenience,
and ease. The Omnipod System consists of two components: (i) a Pod that
stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM)
that wirelessly programs the user’s personalized insulin delivery,
calculates suggested doses and insulin on board, and has a convenient,
built-in blood glucose meter. The small, light-weight Pod can be worn in
multiple locations, including the abdomen, hip, back of upper arm, upper
thigh or lower back and, because it is waterproof (IPX8), there is no
need to remove when showering, swimming or performing other activities.
This means that Omnipod can provide up to three days of non-stop insulin
delivery, without the need to disconnect a tube set or manually inject
insulin. The Pod and PDM communicate wirelessly to offer precise,
personalized and continuous insulin delivery with customizable basal and
bolus delivery options, as well as important safety checks. The Pod’s
auto-cannula insertion is quick, simple, and virtually pain-free. Users
never have to handle a needle. The user simply pushes a button on the
PDM and the Pod’s automated insertion system inserts the cannula beneath
the skin and begins delivering insulin according to the user’s
programmed basal rate.

The Omnipod System is the world’s first commercially available tubeless
insulin delivery system that allows users to live untethered by tubing
and without the stress and anxiety of multiple daily injections. By
breaking down the barriers to insulin pump therapy, the Omnipod System
offers freedom for users to live life on their own terms and with the
ease of use they deserve.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device
company dedicated to making the lives of people with diabetes easier.
Through its Omnipod Insulin Management System, Insulet seeks to expand
the use of insulin pump therapy among people with insulin-dependent
diabetes. The Omnipod is a revolutionary and easy-to-use tubeless
insulin pump that features just two parts and a fully-automated cannula
insertion. Insulet’s Delivery Systems business also partners with global
pharmaceutical and biotechnology companies to tailor the Omnipod
technology platform for the delivery of subcutaneous drugs across
multiple therapeutic areas. To read inspiring stories of people with
diabetes living their lives to the fullest with OmniPod, please visit
our customer blog, Suite D:
Founded in 2000, Insulet Corporation is based in Billerica,
Massachusetts. For more information, please visit:

Forward-Looking Statement:

This press release may contain forward-looking statements
concerning Insulet’s expectations, anticipations, intentions, beliefs or
strategies regarding the future. These forward-looking statements are
based on its current expectations and beliefs concerning future
developments and their potential effects on Insulet. There can be no
assurance that future developments affecting Insulet will be those that
it has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 29, 2016 in the section entitled
“Risk Factors,” and in its other filings from time to time with
the Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its assumptions
prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.

All trademarks are the property of their respective owners.


Insulet Corporation
Investor Relations and Media Contact:
R. Gordon, 978-600-7717
Vice President, Investor Relations and
Corporate Communications